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Abstract: Restless legs syndrome and periodic limb movement disorder of sleep are now 
recognized as prevalent, distinct, yet overlapping disorders affecting all age groups. Although 
delineation of the mechanisms underlying these disorders continues to be the focus of very 
intense research efforts, it has become apparent that there is a prominent role for dopaminergic 
agents in the clinical management of these patients. Among the various dopaminergic drugs, 
ropinirole has undergone relatively intense and critical scrutiny, and appears to provide a safe 
and efficacious treatment option for patients with these two conditions. The more recent devel-
opment of a controlled formulation for this drug is likely to yield additional benefits such as 
improved adherence and reduced fluctuations in daytime and nighttime symptoms. However, 
there is not enough evidence at this time to support such assumption.
Keywords: dopaminergic drugs, restless legs syndrome, ropinirole, period limb movement 
disorder
Restless legs syndrome
Restless legs syndrome (RLS) is a common condition characterized by a tetrad of 
diagnostic criteria that include: (a) leg restlessness, usually accompanied or caused by 
uncomfortable and unpleasant sensations in the legs; (b) beginning or worsening of 
this unpleasant sensation during rest or inactivity such as lying or sitting; (c) partial or 
total relief of the unpleasant sensations by movement, and (d) worsening or occurrence 
of the unpleasant sensations in the evening or night compared to daytime.1,2 RLS is 
thought to affect approximately 3% to 12% of the population,3 and is common across 
the age spectrum from childhood to advanced ages in adults.4 Although RLS has not 
been directly associated with significant bodily harm, it is an important cause of sleep 
deprivation and fragmentation, may induce depression, and can significantly hamper 
the ability to travel by car or flight. As further discussed below, RLS can be primary 
or develop as a consequence of several common conditions or disorders.
The term “restless legs syndrome” was first used by the Swedish neurologist 
Karl-Axel Ekbom in 1945, and constituted the first modern evidence-based approach 
to a phenomenon that until that point had been erroneously presumed to be part of 
the phenotypic expression of hysteria.1 Even though the underlying biochemical and 
neurophysiologic mechanisms of RLS are currently only partially understood, there 
have been some recent advances in clarifying the etiology of this frequent condition.
Dopamine plays an important role in many movement disorders, such as Parkinson’s 
disease,5 Huntington’s disease,6 Wilson’s disease,7 and perhaps also in the regulation 
of sleep.8 In addition to the known contribution of dopaminergic pathways to the Therapeutics and Clinical Risk Management 2010:6 174
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pathophysiology of several movement disorders, there are 
several lines of evidence that support a role for dopamine 
in the pathogenesis of RLS. For example, it is now well 
described that dopamine antagonists will worsen symptoms 
in patients with RLS, and conversely, dopamine agonists are 
associated with beneficial effects.9 Furthermore, the findings 
reported from studies using positron emission tomography 
(PET) and single photon emission computed tomography 
(SPECT) would lend support to this theory.10 Indeed, Allen 
and co-workers showed the presence of abnormal receptor 
binding and transport of dopamine in patients with period 
limb movement disorder (PLMD), a condition that is highly 
prevalent in RLS patients.11 In addition, Staedt and collabo-
rators found evidence for decreased dopamine D2-receptor 
binding in patients with period limb movements of sleep 
(PLMS) compared to control subjects.12,13 However, there 
was no linear correlation between the severity of symptoms 
and the degree of receptor binding. Notwithstanding, patients 
reporting the highest frequency of sleep disruption also had 
the lowest level of receptor binding.12,13 PET studies compar-
ing patients with RLS and PLMS to control subjects have 
also demonstrated decreased dopamine receptor binding in 
the striatum and decreased F-DOPA uptake in the putamen.14 
Michaud et al used SPECT approaches and reported that pre-
synaptic D2-receptor binding was decreased in patients with 
RLS compared to control subjects.15 Therefore, although the 
exact role of dopamine in RLS remains to be elucidated, the 
cumulative findings emanating from these studies strongly 
support the presence of altered dopaminergic pathways in 
RLS patients.
Secondary RLS is commonly seen in conditions such as 
iron deficiency with or without anemia, in patient undergo-
ing dialysis for uremic renal failure, and is also frequently 
observed in pregnancy. The common feature among these 
secondary causes of RLS would implicate a deficiency in 
iron or in iron stores,16 and as such a great deal of interest has 
developed on the role of iron metabolism in the context of 
RLS. For example, oral iron supplementation decreased RLS 
scores when serum ferritin levels were below 0.45 pg/mL, 
but did not seem to have such beneficial effect on RLS 
symptoms when ferritin levels were higher, albeit decreased 
compared to control subjects.17 Despite such findings, serum 
ferritin levels were correlated with RLS score.17,18 However, 
such association could not be reproduced in a larger epi-
demiologic study.19 Earley and co-workers suggested that 
iron deficiency in the central nervous system, rather than 
in the peripheral blood was correlated with RLS symp-
toms based on CSF studies from 16 patients and 8 control 
subjects.20 Indeed, CSF levels of ferritin were significantly 
lower in the study group (mean 1.11 ± 0.25 ng/mL vs 
3.50 ± 0.55 ng/mL, P = 0.0002) versus controls.20 Also, 
imaging studies using T2-weighted MRI and post-mortem 
brain studies have found decreased levels of iron in the 
substantia nigra.21,22 Snyder et al assessed neuronal staining 
patterns of ferritin in the human brain, and found increased 
mitochondrial levels of ferritin in the substantia nigra of 
patients with RLS compared to controls. The authors sug-
gested that decreased cytosolic levels of iron could be a 
key factor in the pathophysiology of RLS.23
Despite such a priori compelling findings, iron replace-
ment therapy has been tried in RLS with variable outcomes. 
For example, a single 1000 mg intravenous iron infusion was 
effective in achieving symptomatic improvements or RLS 
for an average of 6 months. However, long-term compliance 
was poor, and only 10 patients were included in this study.24 
In a 12-months, double-blind, placebo-controlled study, 
60 patients with RLS and iron deficiency were randomized 
to receive either intravenous iron sucrose (n = 29) or placebo 
(n = 31). The RLS score at 11 weeks served as the primary 
endpoint and although lower in the treatment group, it did 
not achieve statistical significance. Other, significant findings 
were fewer withdrawals from the study in the iron sucrose arm 
(n = 9 in treatment vs n = 21 in placebo group, P  0.0006) 
and a higher proportion of responders (50% reduction of 
RLS scores) in the treatment group (P = 0.02).25 A similar, 
albeit smaller study failed however to show any significant 
benefit of intravenous iron sucrose compared to placebo.26 
In an animal model, liver and serum iron levels were shown 
to have a diurnal variation with a 30% to 40% increase in 
liver iron and a 20% to 30% decrease in serum iron during 
the active dark phase. An iron deficient diet eliminated this 
circadian variation, and also decreased central iron stores, 
particularly during the inactive light phase.27 Earley and co-
workers found that lymphocytes of patients with RLS exhib-
ited increased expression of transferrin receptors as well as 
ferroportin.28 Since ferroportin is implicated in cellular iron 
excretion and elevated transferrin is a sign of intracellular 
depletion, these findings suggest the presence of a disrupted 
turnover of iron in RLS. In a patient with RLS and normal 
serum ferritin, a bone marrow biopsy was consistent with 
medullary iron depletion.29 In an attempt to explain the 
relation of iron stores and dopamine function in the central 
nervous system it has been proposed that low central iron 
stores could affect the function of tyrosine hydroxylase. This 
enzyme, which serves as the rate limiting step in dopamine 
synthesis, requires iron as a co-factor, and therefore relative Therapeutics and Clinical Risk Management 2010:6 175
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unavailability of iron in the brain could reduce dopamine 
release. A recent study showed a significant difference in 
the levels of tyrosine hydroxylase expression in post-mortem 
brain studies of RLS patients when compared to controls.30
Although the symptoms of RLS are most prominent in the 
peripheral portions of the lower limbs, it is the central nervous 
system, rather than peripheral nervous system, that appears 
to be involved in RLS pathogenesis.31 Metoclopramide, a 
dopamine antagonist that crosses the blood–brain barrier, 
can markedly worsen symptoms of RLS and neutralize the 
therapeutic effect of dopamine agonists.32 However, dopa-
mine antagonists that do not cross the blood–brain barrier, 
such as domperidone, are void of RLS-exacerbating effects.33 
Functional magnetic resonance imaging (fMRI) has been 
used to study what sites of the brain are involved in invol-
untary leg movements in RLS. Sites that are activated prior 
to involuntary movements include the cerebellum, thalamus, 
inferior olive and red nucleus. These structures receive input 
from a spinal gait generator, and have been suggested to 
form a neuronal loop that induces the symptoms of RLS. 
The cerebral cortex, however, was not activated prior to 
involuntary movements, suggesting that only deeply located 
dopaminergic loci were primarily involved.34
There is a well described familial clustering of RLS. The 
concordance rate among identical twins has been reported 
to be 80%,35 and more than half of all patients have a first-
degree relative with RLS.36 It is also known that familiar 
cases of RLS tend to present at an earlier age, and have 
a more indolent course than sporadic cases.37 The mode 
of inheritance, however, remains to be fully understood. 
Genetic linkage studies have suggested a locus on chromo-
some 12q and autosomal recessive transmission.38 However, 
autosomal dominant transmission with loci on chromosome 
14q, 9p, 20p and 2q has also been proposed.39–42 Two large 
scale genome-wide association studies involving a German/
Canadian and Icelandic/American populations have thus far 
attempted to locate candidate genes implicated in RLS patho-
physiology.43,44 Although several genes (eg, MEIS1, BTBD9, 
MAP2K5, LBXCOR1) were identified as potential candidate 
genes, their functions are highly heterogenic, and as such, 
the implications of these findings are difficult to interpret.43,44 
Of note, the strongest association between candidate genes 
and phenotype was found for PLMS, rather than for RLS, at 
least in the Icelandic/American study.44
Periodic limb movements in sleep
PLMS is a condition characterized by episodes of repetitive 
movements of the lower limbs involving toe extension and 
dorsiflexion of the ankle during sleep.45 PLMS is intimately 
associated with RLS, affecting about 80% of RLS patients, 
but also occurs commonly in other sleep and movement dis-
orders, such as obstructive sleep apnea syndrome, idiopathic 
insomnia or hypersomnia, Parkinson’s disease, and Gilles de 
la Tourette syndrome.46–48 The standard criteria to diagnose 
PLMS include 4 consecutive stereotypical movements lasting 
0.5 to 10 seconds, separated by 10 to 90 seconds.49,50 PLMD 
is the occurrence of PLMS with the addition of an otherwise 
unexplained sleep complaint.51,52
The prevalence of PLMS is reported to be 4% to 11% 
in adults with increasing occurrence in the elderly.53 The 
prevalence in the pediatric age group is lower, with RLS 
being reported in 2% of children in the community, and 
PLMD being reported in 5.6% of children referred to a 
sleep center.54,55 Asymptomatic PLMS seems to be rare in 
children, but becomes increasingly common with advancing 
age,56 and preliminary evidence suggests that asymptomatic 
PLMS might explain some cases of an otherwise unexplained 
complaint of insomnia.57
As with RLS, subcortical structures seem to be respon-
sible for the abnormal movements. PLMS have been docu-
mented in patients with spinal cord transection.58 Also, the 
absence of pre-motor cortical potentials preceding PLMS 
further suggests a role for central subcortical structures 
rather cortical or spinal mechanisms.59,60 However, even 
if there seems to be no PLMS phase-locked EEG activity 
preceding the events, independent more recent studies have 
demonstrated the existence of temporal alignments between 
EEG activity and PLMS events;61,62 thus, the involvement 
of cortical structures cannot be excluded with certainty. We 
should also note that PLMS may be induced by electronic 
stimulation of the peroneal nerve at the level of the fibular 
head.59
PLMS events are also accompanied by important transient 
autonomic changes involving heart rate61–64 and blood pres-
sure,65,66 and such sympathetic activation has led to prelimi-
nary evidence implicating PLMD and an increased risk for 
cardiovascular and cerebrovascular morbidities.67
The role of iron stores and dopamine has been less 
thoroughly investigated in PLMS than in RLS, and in most 
studies there is significant overlap between the two enti-
ties. However, some common pathophysiological features 
seem to coincide in both conditions. For example, central 
nervous system iron deficiency,67,68 and relative reductions 
in dopamine availability, such as occurs during late evenings 
and early nights, coincident with the circadian nadir of dopa-
mine.69,70 Further studies have suggested a dysfunction in a Therapeutics and Clinical Risk Management 2010:6 176
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hypothalamically located dopaminergic nucleus (A11) to be 
responsible for symptoms of RLS as well as PLMS.71 Finally, 
dopamine preparations are effective treatment options in 
both conditions.
Ropinirole
Dopamine agonists are currently considered as the first-line 
treatment in RLS. Ropinirole was the first FDA-approved 
pharmacological agent for moderate to severe primary RLS.72 
Ropinirole is classified as a non-ergolide dopamine agonist, 
and has affinity for the D2 and D3 receptor subtypes, but 
minimal affinity for the D1 receptor subtype. In addition, 
ropinirole has no affinity or very low affinity for receptors 
of other common neurotransmitters. Ropinirole binds to 
both central and peripheral dopamine receptors with variable 
activity and binding sites. Centrally, its affinity and activity 
at the D3 receptor is 20 times higher than at the D2 recep-
tor and it binds to post-synaptic receptors.73–75 The putative 
mechanism of action in the central nervous system is similar 
to that of endogenous dopamine, both in terms of post-
synaptic effects and inhibitory feedback, thereby limiting 
further dopamine release. In the periphery, ropinirole binds 
to pre-synaptic D2 receptors eliciting a sympathomimetic 
response. This effect of ropinirole may be associated with 
increases in blood pressure and nausea, both of which can 
be attenuated by proceeding with slow increases in dosage 
till reaching therapeutic levels.76,77
Approximately 90% of radioactively labeled ropinirole 
is excreted in the urine, whether the drug was intravenously 
or orally, which suggests near complete absorption from the 
gut and a primarily renal disposition of the drug, which is 
however metabolized by the liver through N-depropylation.78 
The N-despropyl metabolite is then further metabolized to 
form 7-hydroxy and carboxylic acid derivatives, which are 
then excreted in urine.78 Time to maximal plasma concentra-
tion (Tmax) ranges from 0.5 to 4 hours, with maximal plasma 
concentration (Cmax) generally occurring at 1.5 hours. Oral 
ropinirole has a bioavailability of approximately 50% and 
the elimination half-life is about 3 hours.79 As with other 
lipophilic amines, absorption for ropinirole is fast and the dis-
tribution volume is extensive. At steady state, oral ropinirole 
has a volume of distribution of about 7.2 L/kg. Plasma protein 
binding is 10% to 40% at all plasma concentrations.80,81 The 
metabolites are not active and all pharmacological proper-
ties can be attributed to the original compound. The liver 
enzyme CYP1A2 and to a much lesser extent CYP1A3 of the 
cytochrome P450 system are responsible for the metabolism 
of ropinirole.78,82,83 This is clinically important, since there is 
great inter-individual variability in the activity of CYP1A2. 
Also, CYP1A2 can be induced by smoking and other drugs.84 
Irrespective of the dosage, the terminal elimination half-life 
of ropinirole ranges from 2 to 10 hours, with a mean of 
6 hours, and as mentioned above, the drug metabolites are 
excreted in the urine.78,85
Administering ropinirole 3 times daily compared to once 
daily resulted in a 2-fold increase in Cmax and in the area under 
the concentration time-curve (AUC). However, clearance of 
the drug was not significantly different under the two dosage 
regimens. Administration of single doses of 2 to 12 mg rop-
inirole increased the Cmax and AUC in a proportional fashion, 
supporting the presence of a linear pharmacokinetic profile.85 
Although the effect is small, food intake does affect plasma 
concentration of ropinirole. A fat-rich breakfast decreased the 
Cmax by 25%, and delayed the Tmax by 2.6 hours, compared to 
fasting. Also a 13% decrease in AUC was noted. Although 
significant, these effects are unlikely to impose a significant 
clinical impact.86
Compared to younger subjects, clearance of ropinirole 
was slower in persons older than 65 years. Also, women 
taking hormonal replacement therapy had slower clear-
ance. However, mild renal impairment, gender, common 
co-morbitites and common drugs did not seem to markedly 
affect ropinirole clearance. Ciprofloxacine, an inhibitor of 
CYP1A2 did increase plasma levels of ropinirole when these 
two drugs were co-administered. In contrast, theophylline 
which is a substrate for CYP1A2 did not affect plasma levels 
of ropinirole.87,88 In summary, ropinirole has a good safety 
profile, it has a linear pharmacokinetic profile and high bio-
availability, and a wide therapeutic window with few reported 
side effects. It can be used in most age groups, even though 
it has yet to be tested in children.
Clinical trials
There have been several studies investigating the effective-
ness of ropinirole in RLS. However, in this review only 
randomized, placebo-controlled trials were included.
The role of ropinirole in RLS plus PLMS was studied 
in a double-blinded, placebo-controlled 12-week trial.89 
Primary RLS was diagnosed based on the international 
RLS study group (IRLSSG) criteria. Additional criteria 
include a PLMS index (PLMS-I)  5 per hour total sleep 
time (hrTST), an IRLS score  15, and a subject report 
of at least 15 nights with RLS symptoms in the 30 nights 
preceding the study. Of the 65 patients who met inclusion 
criteria, 59 subjects completed polysomnography (PSG) 
assessments, and were included in the study. Of these, Therapeutics and Clinical Risk Management 2010:6 177
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29 patients (17 women; mean age: 55.4 ± 10.3 years, 
range: 37 to 76) were randomized to the ropinirole group 
and 30 subjects (17 women; mean age: 53.3 ± 12.5 years, 
range: 30 to 79) were assigned to the placebo group. In the 
ropinirole-treatment arm, PLMS-I decreased from 48.5/
hrTST to 11.5/hrTST, a significant improvement compared 
to the placebo group (35.7/hrTST to 34.2/hrTST; adjusted 
treatment difference: −27.2/hrTST; 95% confidence inter-
val [CI] −39.1 to −15.4/hrTST; P  0.0001). Similarly, the 
PLMS-I that was associated with arousals decreased from 
7.0/hrTST to 2.3/hrTST in the treatment group versus an 
increase from 4.2/hrTST to 6.0/hrTST in the placebo group 
(adjusted treatment difference: −4.3/hrTST; 95% CI: −7.6 to 
−1.1/hrTST: P = 0.01). Interestingly, the PLM index during 
wakefulness (PLMW) also decreased from 56.5/hr to 23.6/hr 
with ropinirole, while it actually increased (from 46.6/hr to 
56.1/hr) with placebo (adjusted treatment difference: −39.5/
hr; 95% CI: −56.9 to −22.1/hr; P  0.0001). Ropinirole 
also was superior to placebo in initiating sleep (P  0.05) 
and NREM stage 2 sleep (P  0.001). The placebo group, 
however, had an increase in NREM stage 3 and 4 sleep 
(P  0.01). Sleep adequacy, as measured by the subjective 
Medical Outcomes Study sleep scale, was improved in the 
ropinirole group compared to the placebo group (adjusted 
treatment difference: 12.1; 95% CI: 1.1 to 23.1; P  0.04). 
No significant negative outcomes were reported for either 
group. The results of this study suggested that ropinirole was 
safe and effective in treating symptoms of RLS with PLMS 
both during sleep and wake.
A smaller double-blind, placebo-controlled, crossover 
study that included 22 patients (16 women; mean age: 60 ± 
13 years, range 40 to 83 years) with a diagnosis of primary 
RLS based on the IRLSSG criteria has also been published.90 
The main outcomes were the changes in the IRLS and ESS 
scales, and also included biweekly entries in an RLS diary. 
The patients were randomized to either 4 weeks of ropinirole 
(0.5 to 6.0 mg/day) followed by 4 weeks of placebo or vice 
versa. To exclude interference of ongoing medications, all 
subjects discontinued RLS medications 2 weeks prior to the 
baseline visit. The mean doses of ropinirole and placebo were 
4.6 mg/day (range: 1 to 6 mg) with 14 of the 22 subjects 
taking 6 mg/day (vs 5.9 mg/day placebo). Mean RLS scores 
were 13 ± 12 in the ropinirole treatment period compared to 
24.7 ± 7.2 in the placebo treatment period (P  0.001) at the 
end of the 4 weeks. Complete resolution of symptoms (RLS 
score = 0) was achieved in 36% (8 of 22) in the ropinirole 
group as compared to none in the placebo group. However, 
there were no changes in ESS scores after either ropinirole 
or placebo. 19 patients completed RLS diaries and the mean 
rate of RLS was 23% in the placebo group compared to 
12% in the treatment group. Two subjects discontinued their 
participation in the ropinirole group during treatment (one 
because of lack of response and the other because of nausea, 
vomiting and dizziness). One patient abandoned during 
placebo treatment because of syncope. The overall efficacy 
was a 50% reduction of RLS symptoms while receiving 
ropinirole based on RLS scores and the diary.
An international multi-center, randomized, placebo-
controlled, double-blind study assessed the effectiveness and 
safety of ropinirole in RLS.91 Centers from America, Europe 
and Australia recruited a total of 267 patients with moderate-
to-severe RLS as per IRLSSG criteria with a baseline score 
of  15 and RLS symptoms being present during at least 
15 of the 30 days prior to the study. Patients discontinued all 
drugs known to affect RLS or sleep for 7 days or more before 
the baseline visit. Patients were then randomized to receive 
either ropinirole (0.25 to 4 mg/day) or placebo 3 hours before 
bedtime once daily. A total of 131 patients (76 females; mean 
age: 54.9 ± 10.8 years, range 29 to 77 years) were included 
in the treatment group and 136 patients (83 females; mean 
age: 56.0 ± 11.2 years, range 29 to 79 years) in the placebo 
group. Primary outcome was defined as the change in IRLS 
score at 12 weeks. Secondary outcomes included the IRLS 
score at 1 week and changes in Clinical Global Impression-
Improvement (CGI-I) score at 1 and 12 weeks. Scores on 
RLS Quality of Life questionnaire and Medical Outcomes 
Study scale were also assessed. IRLS scores at 12 weeks were 
significantly better in the ropinirole treatment arm compared 
to the placebo group (−11.2 ± 0.76 vs −8.7 ± 0.75; adjusted 
treatment difference: −2.5; 95% CI: −4.6 to −0.4; P  0.02). 
No severe adverse effects were reported. Thus, ropinirole 
emerged as superior to placebo in improving RLS symptoms 
as well as quality of life, and was globally well tolerated.
An European multi-center, randomized, placebo-
controlled study has also evaluated the efficacy and safety of 
ropinirole in RLS.92 The study duration was 12 weeks and 284 
patients from 10 countries participated in the study. Inclusion 
criteria included an IRLS score of 15 or above. Treatment 
consisted of ropinirole 0.25 to 4 mg daily and was compared 
to placebo. A total of 146 subjects (88 females; mean age: 
54.0 ± 11.1 years, range 30–78 years) was randomized to 
the treatment group and 138 (91 females; mean age: 56.2 ± 
11.2 years, range 28 to 77 years) to the placebo group. The 
primary outcome endpoint was the change in IRLS score 
at 12 weeks. Changes in Clinical Global Impression (CGI) 
scale, improvements in sleep, health related quality of life and Therapeutics and Clinical Risk Management 2010:6 178
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other outcomes were also assessed. From the randomization 
baseline, 76.7% (112/146) in the ropinirole group and 79.0% 
(109/138) in the placebo group completed the study. Improve-
ments in IRLS scores at 12 weeks were significantly greater in 
the ropinirole group (−11.04 ± 0.72) versus placebo (−8.03 ± 
0.74; adjusted treatment difference: −3.01; 95% CI: −5.03 
to −0.99; P = 0.0036). A significantly higher percentage of 
subjects in the ropinirole group had improvements on the 
CGI scale (53.2% vs 40.9%; adjusted odds ratio = 1.7; 95% 
CI: 1.02 to 2.69; P = 0.0416). These improvements in IRLS 
score and on the CGI scale were noted at week 1. Improve-
ments in sleep quality and quality of life were also greater in 
the treatment group. Adverse outcomes included headache 
and nausea, but no severe adverse effects were reported. In 
summary, ropirinole improved symptoms and quality of life 
in patients with RLS and was not associated with serious 
adverse effects.
Another randomized, placebo-controlled 6-week duration 
study to assess the efficacy of ropinirole in RLS patients 
included 22 patients (13 women; mean age: 50.8 years, 
range: 46. 5 to 55.2) that had undergone 4 weeks open-label 
titration prior to baseline.93 Nine subjects were randomized to 
the ropinirole group and 13 to the placebo group. Treatment 
consisted in a dosage ranging from 0.25 mg to 6 mg ropinirole 
at bedtime vs placebo at bedtime. Primary efficacy end points 
at 2 weeks in addition to the 4 weeks of titration were PLMS 
assessed by nocturnal PSG, and differences in the score on 
the IRLSSG rating scale. In the treatment group, a significant 
decrease in PLMS and RLS symptoms was noted. The mean 
administered dose of ropinirole was 1.4 mg. The PLMS-I 
during NREM sleep in the treatment group was 19.7/hrTST 
(range 0 to 45.6/hrTST) at week 4 and 19.8/hrTST (range 
0 to 44.4/hrTST) at week 6. PLMS-I in the placebo group 
was 19.2/hrTST (range 4.6 to 33.9/hrTST) at week 4 and 
76.4/hrTST (37.3 to 115.5/hrTST) at week 6, indicating 
a significant worsening after transition to the placebo. All 
patients completed the study. No severe adverse effects were 
reported although dose-related side-effects included nausea, 
headache and daytime somnolence. The authors concluded 
that ropinirole is more effective than placebo at reducing 
PLMS in RLS patients.
To study the effectiveness and tolerability of ropinirole 
in RLS, a multicenter, double-blind, placebo-controlled 
study was conducted over 12 weeks.94 381 patients with 
RLS were included. 187 were randomized to receive pla-
cebo (109 female; mean age 52.2 ± 12.8 years, range 18 to 
79 years) and 194 to receive (123 female; mean age 52.4 ± 
13.1 years, range 19 to 78 years) 0.25 to 4.0 mg ropinirole 
as needed, once daily, 1 to 3 hours before bedtime. Primary 
outcome was the change in IRLS score at 12 weeks. Second-
ary outcome included the changes in CGI-I score. About 
87.7% (164/187) of the subjects in the treatment group and 
86.1% (167/194) in the placebo group completed the study. 
Ropinirole significantly improved IRLS scores compared 
to placebo at week 12 (adjusted mean treatment difference: 
−3.7; 95% CI: −5.4 to −2.0; P  0.001). Mean changes in 
IRLS scores at 1 week and changes in CGI-I scale at week 1 
and 12 were also significantly improved in the treatment 
group. Also, ropinirole was superior to placebo in subjec-
tively assessed sleep disturbance and quantity, anxiety and 
quality of life. Of note, there was a trend towards decreased 
daytime sleepiness in the treatment group (P = 0.10). Simi-
larly, 7 patients in the ropinirole group and 9 in the placebo 
group left the study due to adverse events of which none 
were unexpected or severe.
Ropinirole controlled release 
formulation
Ropinirole controlled release (CR), is a new developed for-
mulation of the drug, that has yet to be specifically approved 
for RLS, but is approved for the treatment of Parkinson’s 
disease. As with many other controlled release formulation 
drugs, ropinirole CR has a more constant serum concentration 
when compared to three times daily dosing of ropinirole. The 
peak to trough ratio (Cmax/Cmin) is 1.9 for ropinirole CR com-
pared to 5 for standard ropinirole dosed three times daily. The 
Cmax is around 12% lower, but the Cmin and AUC are similar. 
Also, in the range of 2 to 8 mg daily, ropinirole CR behaves 
in a dose-dependent linear manner.95 The side effect profile 
is similar to ropinirole immediate release (IR) and no new 
or unknown side effects have been identified thus far. Initial 
experience in the treatment of Parkinson’s disease has failed 
to reveal any complications in switching from ropinirole IR 
or any other dopamine agonists to ropinirole CR.96,97
Data on ropinirole CR in RLS were gathered essentially 
from unpublished data available from GSK-GlaxoSmith-
Kline.98 We will briefly describe these data; however, as a 
cautionary note, it should be emphasized that such reports 
may be affected by potential bias because of the source of 
this information. We would also like to specify that there is 
no conflict of interest for any of the authors of this article in 
relation to the analysis of such data.
A phase II, open-label, uncontrolled clinical evaluation 
of ropinirole CR for RLS (CR-RLS) showed improvement 
in RLS symptoms with a mean decrease in IRLS of −19.3 
and a mean change of PSQI of 4.3 from baseline, thus Therapeutics and Clinical Risk Management 2010:6 179
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  suggesting the potential efficacy of ropinirole in Japanese 
subjects affected by idiopathic RLS.98 However, in the safety 
evaluation, adverse events on therapy were observed in 
33 subjects (94%); of these a direct assignment of ropinirole 
CR to the side-effect was found in 29 subjects (83%). Most 
of the adverse events were mild or moderate in nature, and 
included nausea (43%), nasopharyngitis (34%), somnolence 
and vomiting (each 14%).
Other studies available are phase III trials. A 12-week, 
double-blind, placebo-controlled, parallel-group study to 
assess the efficacy and safety of ropinirole CR for RLS 
(CR-RLS) in patients with RLS (SK&F-101468/205), found 
an adjusted mean IRLS change from baseline of ∼15.4 
after ropinirole vs ∼9.6 after placebo (P  0.001).99 The 
percentage of responders on the CGI-I Scale was 79% after 
ropinirole CR vs 50% after placebo (P  0.001). At least 
one adverse event was reported by 76% of patients taking 
ropinirole CR and 68% of those treated with placebo; the 
most common adverse events after ropinirole were nausea, 
headache, somnolence, dizziness and vomiting. Two patients 
treated with ropinirole CR showed serious (non-fatal) 
adverse events (vasovagal syncope and status asthmaticus) 
vs one patient treated with placebo (viral meningitis).
In the final report of the same study, these results were 
essentially confirmed. From these unpublished data, it was 
concluded that on-treatment adverse events were reported for 
345 (89%) subjects, with the most frequently reported being 
nausea (26%) and headache (21%).100 On-treatment severe 
adverse events were reported for 19 (5%) subjects; those 
reported for more than 1 subject were cellulitis (3 subjects, 
1%) and cholelithiasis (2 subjects, 1%). No fatal severe 
adverse events were reported.
Another trial evaluated the safety and tolerability of con-
verting from ropinirole immediate release (IR) to ropinirole 
CR in patients with RLS.101 No substantial changes in IRLS 
or CGI-I were observed, and there were no new or unexpected 
adverse events or other safety results seen with conversions 
from ropinirole IR to ropinirole CR.
Finally, a study was conducted to confirm the effective-
ness, safety, and tolerability of ropinirole CR in reducing 
RLS sleep disturbance and PLMS. In this study, sleep 
was recorded polysomnographically in a relatively small 
group of patients (n = 17).102 PLMS index was found to be 
decreased after 12 weeks of treatment with ropinirole CR; 
however, the decrease was not significantly different from 
the changes seen in the placebo group.102 However, the index 
of PLMS associated with arousals showed a more marked 
decrease while on treatment than in the placebo group. 
  Notwithstanding such statements, statistical analyses were 
not provided. This is true also for other polysmnographic 
parameters as well as for subjective sleep evaluation items. 
For this reason, it is impossible to extrapolate any specific 
conclusions from this study.
Summary
The relatively high prevalence and increasing awareness to 
RLS and PLMD has prompted exploration of not only the 
theoretical pathophysiological mechanisms that underlie this 
condition, but has also instigated a large array of clinical trials 
with several agents such as iron or dopamine agonists. Among 
the latter, ropinirole IR has emerged as a relatively safe and 
efficacious therapeutic approach, albeit with some uncertainty 
as to its role in selected populations, such as children, for 
whom data are currently unavailable. Similarly, develop-
ment of a controlled release formulation for ropinirole may 
provide additional advantages such as increased adherence 
and improved outcomes, but the data at the moment remain 
too limited to draw any definitive conclusions.
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